Gene Variants Associated With Deep Vein Thrombosis

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
JAMA The Journal of the American Medical Association (Impact Factor: 30.39). 03/2008; 299(11):1306-14. DOI: 10.1001/jama.299.11.1306
Source: PubMed

ABSTRACT The genetic causes of deep vein thrombosis (DVT) are not fully understood.
To identify single-nucleotide polymorphisms (SNPs) associated with DVT.
We used 3 case-control studies of first DVT. A total of 19 682 gene-centric SNPs were genotyped in 443 cases and 453 controls from the Leiden Thrombophilia Study (LETS, 1988-1992). Twelve hundred six SNPs associated with DVT were reinvestigated in the Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study (MEGA-1, 1999-2004) in a subset of 1398 cases and 1757 controls. Nine SNPs associated with DVT in both LETS and MEGA-1 were investigated a third time in 1314 cases and 2877 controls from MEGA-2, a second subset of MEGA. Additional SNPs close to one SNP in CYP4V2 were genotyped in LETS and MEGA-1.
Odds ratios (ORs) for DVT were estimated by logistic regression. False discovery rates served to investigate the effect of multiple hypothesis testing.
Of 9 SNPs genotyped in MEGA-2, 3 were strongly associated with DVT (P < .05; false discovery rate < or =.10): rs13146272 in CYP4V2 (risk allele frequency, 0.64), rs2227589 in SERPINC1 (risk allele frequency, 0.10), and rs1613662 in GP6 (risk allele frequency, 0.84). The OR for DVT per risk allele was 1.24 (95% confidence interval [95%CI], 1.11-1.37) for rs13146272, 1.29 (95% CI, 1.10-1.49) for rs2227589, and 1.15 (95% CI, 1.01-1.30) for rs1613662. In the region of CYP4V2, we identified 4 additional SNPs (in CYP4V2, KLKB1, and F11) that were also associated with both DVT (highest OR per risk allele, 1.39; 95% CI, 1.11-1.74) and coagulation factor XI level (highest increase per risk allele, 8%; 95% CI, 5%-11%).
We identified SNPs in several genes that were associated with DVT. We also found SNPs in the region around the SNP in CYP4V2 (rs13146272) that were associated with both DVT and factor XI levels. These results show that common genetic variation plays an important role in determining thrombotic risk.

Download full-text


Available from: Carine J M Doggen, Aug 14, 2015
  • Source
    • "Twin and family studies suggest that VTE is highly heritable , with heritability estimates ranging from 0.5 to 0.6 [Heit et al., 2004; Larsen et al., 2003; Souto et al., 2000]. A growing number of genetic variants, most in the coagulation and fibrinolysis pathways, have been consistently linked to VTE [Anderson and Spencer, 2003; Bezemer et al., 2008; Blondon et al., 2011; Cushman, 2007; Dennis et al., 2012; Emmerich et al., 2001; Germain et al., 2011; Heit et al., 2012; Lowe, 2006; Rosendaal, 1999a, b; Smith et al., 2007; Tregouet et al., 2009]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Venous thromboembolism (VTE) is a common, heritable disease resulting in high rates of hospitalization and mortality. Yet few associations between VTE and genetic variants, all in the coagulation pathway, have been established. To identify additional genetic determinants of VTE, we conducted a two-stage genome-wide association study (GWAS) among individuals of European ancestry in the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) VTE consortium. The discovery GWAS comprised 1,618 incident VTE cases out of 44,499 participants from six community-based studies. Genotypes for genome-wide single-nucleotide polymorphisms (SNPs) were imputed to approximately 2.5 million SNPs in HapMap and association with VTE assessed using study-design appropriate regression methods. Meta-analysis of these results identified two known loci, in F5 and ABO. Top 1,047 tag SNPs (P ≤ 0.0016) from the discovery GWAS were tested for association in an additional 3,231 cases and 3,536 controls from three case-control studies. In the combined data from these two stages, additional genome-wide significant associations were observed on 4q35 at F11 (top SNP rs4253399, intronic to F11) and on 4q28 at FGG (rs6536024, 9.7 kb from FGG; P < 5.0 × 10(-13) for both). The associations at the FGG locus were not completely explained by previously reported variants. Loci at or near SUSD1 and OTUD7A showed borderline yet novel associations (P < 5.0 × 10(-6) ) and constitute new candidate genes. In conclusion, this large GWAS replicated key genetic associations in F5 and ABO, and confirmed the importance of F11 and FGG loci for VTE. Future studies are warranted to better characterize the associations with F11 and FGG and to replicate the new candidate associations.
    Genetic Epidemiology 05/2013; 37(5). DOI:10.1002/gepi.21731 · 2.95 Impact Factor
  • Source
    • "The FV G1691A mutation results in an Arg-to-Glu substitution at codon 506, which makes the coagulation protein resistant to proteolytic inactivation by activated protein C and, subsequently, increases fibrin formation (Bertina et al., 1994). Carriers of this mutation have a 4-to 12-fold greater risk of developing VTE (Torres et al., 2006; Bezemer et al., 2008; Alfirevic et al., 2010). Furthermore, the risk of VTE recurrence in heterozygous persons is approximately 40% higher than it is in persons without the mutation (Marchiori et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Venous thromboembolism (VTE) is an important cause of morbidity and mortality stemming from cardiovascular disease. It is a multifactorial disease caused by a combination of acquired risk factors, of which advanced age is the most significant, and genetic factors, including the variants FV G1691A, FII G20210A, and MTHFR C677T. We estimated the prevalence of these genomic variants in an elderly population of northeastern Brazil. The study included 188 elderly persons (65-93 years), of which 68 (36.2%) were men and 120 (63.8%) were women. Variants were detected by polymerase chain reaction-restriction fragment length polymorphism analysis, and subsequent electrophoresis on an 8% polyacrylamide gel stained with silver nitrate. The study population was in Hardy-Weinberg equilibrium for the 3 loci. Of the individuals analyzed, none carried variants of FV or FII (0%), and 24.7% had the MTHFR C677T polymorphism: 59 subjects (31.4%) were heterozygous (CT) and 17 subjects (9%) were homozygous (TT). Based on the analysis of these particular genes, we conclude that the study population does not present with an increased risk for the development of VTE. Faced with a growing aging population worldwide, similar studies in other countries will help in the prevention of VTE in older individuals.
    Genetics and molecular research: GMR 03/2013; 12(AOP). DOI:10.4238/2013.Mach.11.5 · 0.85 Impact Factor
  • Source
    • "Many of these conditions share a hypercoagulable state leading to thrombosis. Venous thromboembolism (VTE) is a multifactorial disease with an incidence in the general population of about 1–2 cases per 1000 personyears [26], that develops with no apparent cause in a substantial proportion of cases [27]. Data on the potential mechanistic role of high MP levels are scanty and contrasting. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating microparticles (MPs) may trigger a hypercoagulable state, leading to thrombotic complications. Data on their association with venous thromboembolism (VTE) are few and inconsistent. To investigate whether or not high levels of MPs are associated with an increased risk of VTE, we carried out a case-control study on 186 patients with a first, objectively diagnosed, episode of VTE and 418 healthy controls. Plasma levels of circulating MPs were measured by flow cytometry. Patients had higher median plasma levels of total MPs than controls (2184 per μL vs 1769 per μL, p<0.0001). The risk of VTE increased progressively with increasing MPs, with a linear dose-response effect in the log odds. Individuals with MPs above the 90th percentile of the controls' distribution (P(90) = 3263 per μL) had a 5-fold increased risk of VTE than those with MPs below the 10th percentile of controls (P(10) = 913 per μL), independently of sex, age, body mass index, thrombophilia, and plasma factor VIII levels [adjusted odds ratio: 5.30 (95%CI: 2.05-13.7)]. Using the 95th percentile of controls as cut-off (P(95) = 4120 per μL), the adjusted odds ratio was 2.20 (1.01-4.79) for individuals with MPs>P(95) compared with those having MPs ≤ P(95). After exclusion of individuals with antiphospholipid antibodies and hyperhomocysteinemia, the interaction between MPs>P(95) and thrombophilia increased the VTE risk from 1.63 (0.60-4.50) to 6.09 (1.03-36.1). High levels of circulating MPs are a possible independent risk factor for VTE.
    Thrombosis Research 09/2011; 129(5):591-7. DOI:10.1016/j.thromres.2011.08.020 · 2.43 Impact Factor
Show more